Editing Platelet (section)

====Indications====
[[Platelet transfusion]] is most frequently used to correct unusually low platelet counts, either to prevent spontaneous bleeding (typically at counts below 10×10<sup>9</sup>/L) or in anticipation of medical procedures that necessarily involve some bleeding. For example, in patients undergoing [[surgery]], a level below 50×10<sup>9</sup>/L is associated with abnormal surgical bleeding, and [[regional anaesthetic]] procedures such as [[epidural]]s are avoided for levels below 80×10<sup>9</sup>/L.<ref name="pmid19775301">{{cite journal |vauthors=van Veen JJ, Nokes TJ, Makris M |title=The risk of spinal haematoma following neuraxial anaesthesia or lumbar puncture in thrombocytopenic individuals |journal=British Journal of Haematology |volume=148 |issue=1 |pages=15–25 |date=January 2010 |pmid=19775301 |doi=10.1111/j.1365-2141.2009.07899.x |doi-access=free}}</ref> Platelets may also be transfused when the platelet count is normal but the platelets are dysfunctional, such as when an individual is taking aspirin or [[clopidogrel]].<ref>{{cite book |veditors=Roback J, Grossman B, Harris T, Hillyer C |title=Technical Manual |edition=17th |date=2011 |publisher=AABB |location=Bethesda MD |isbn=978-1-56395-315-6 |oclc=756764486 |author=American Association of Blood Banks |page=580}}</ref> Finally, platelets may be transfused as part of a [[massive transfusion protocol]], in which the three major blood components (red blood cells, plasma, and platelets) are transfused to address severe [[hemorrhage]]. Platelet transfusion is contraindicated in [[thrombotic thrombocytopenic purpura]] (TTP), as it fuels the [[coagulopathy]].  Platelet transfusion is generally ineffective, and thus contraindicated, for prophylaxis in [[immune thrombocytopenia]] (ITP), because the transfused platelets are immediately cleared; however, it is indicated to treat bleeding.<ref>{{cite journal |vauthors=Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, González-López TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ |title=Updated international consensus report on the investigation and management of primary immune thrombocytopenia |journal=Blood Adv |volume=3 |issue=22 |pages=3780–3817 |date=November 2019 |pmid=31770441 |pmc=6880896 |doi=10.1182/bloodadvances.2019000812 }}</ref>